Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sigmapharm arzneimittel gmbh - natrium pentosan polysulfat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sigmapharm arzneimittel gmbh - natrium pentosan polysulfat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sigmapharm arzneimittel gmbh & co kg - natrium pentosan polysulfat,7-isopropyl-1,4-dimethylazulen - heparinoid, kombination

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bene - arzneimittel gmbh (3072164) - pentosanpolysulfat-natrium - gel - teil 1 - gel; pentosanpolysulfat-natrium (05818) 1,5 gramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bene - arzneimittel gmbh (3072164) - pentosanpolysulfat-natrium - salbe - teil 1 - salbe; pentosanpolysulfat-natrium (05818) 0,1 gramm

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - heparinum - kommen 50'000 e - heparinoidum (natrii pentosani polysulfas) 15 mg corresp. heparinum 500 u.i., carbomerum 940, trolaminum, alcohol isopropylicus, melissae aetheroleum, pini pumilionis aetheroleum, rosmarini aetheroleum, aqua purificata ad gelatum pro 1 g corresp., limonenum 0.132 mg, citronellolum 0.015 mg, citralum 0.015 mg, geraniolum 0.0375 mg. - beschwerden bei krampfadern, stumpfe verletzungen - synthetika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bene - arzneimittel gmbh - aluminium-dihydroxid-stearat, guajazulen, pentosanpolysulfat-natrium - zäpfchen - aluminium-dihydroxid-stearat 30.mg; guajazulen 0.1mg; pentosanpolysulfat-natrium 3.mg

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

nutrimedis sa - heparinoidum (natrii pentosani polysulfas) - salbe - heparinoidum (natrii pentosani polysulfas) 1 mg endwerte. heparinum 33.3 u. i., propylenglycolum, conserv.: e 200, e 216, e 218, excipiens ad-salbe für 1 g. - beschwerden bei krampfadern, stumpfen verletzungen - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpura, thrombotische thrombozytopenische - antithrombotische mittel - cablivi ist indiziert für die behandlung von erwachsenen erleben eine episode der erworbenen thrombotischen thrombozytopenische purpura (attp) in verbindung mit plasma-austausch und immunsuppression.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.